Filing Flows › Recursion Pharmaceuticals (RXRX) › Q3 2026 › vs Q2 2026
Recursion Pharmaceuticals (RXRX) Q3 2026 vs Q2 2026 (quarter over quarter)
Recursion Pharmaceuticals's revenue rose $10.9M (+142%) from $7.7M in Q2 2026 to $18.6M in Q3 2026. The biggest changes: Operating revenue +$10.8M (+147%); Grant revenue +$130K (+35%).
Recursion Pharmaceuticals, Q3 2026: revenue $18.6M (+258% year over year), operating margin -663.9%, net loss $119M, operating cash flow −$77.4M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Operating revenue | $18.1M | $7.3M | $10.8M | +147% |
| Grant revenue | $497K | $367K | $130K | +35% |
| Revenue | $18.6M | $7.7M | $10.9M | +142% |
| Other income, net | $4.2M | $4.0M | $203K | +5% |
| Net loss | $119M | $131M | −$12.0M | -9% |
| Costs & expenses | $142M | $143M | −$885K | -0.6% |
| Operating costs | $142M | $143M | −$910K | -0.6% |
| Income tax | $25K | −$1K | $26K | — |
| Cost of revenue | $10.0M | $11.5M | −$1.4M | -13% |
| Research & development | $99.1M | $89.6M | $9.5M | +11% |
| General & admin | $32.6M | $41.5M | −$9.0M | -22% |
| Operating cash sources | $119M | $131M | −$12.0M | -9% |
| Depreciation & amortization | $16.5M | $18.2M | −$1.6M | -9% |
| Share-based compensation | $23.0M | $19.5M | $3.5M | +18% |
| Working capital & other | $2.1M | −$12.6M | $14.7M | — |
| Cash used in operations | $77.4M | $106M | −$28.5M | -27% |
| Net loss absorbed | $119M | $131M | −$12.0M | -9% |
Questions
How much did Recursion Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Recursion Pharmaceuticals's revenue rose $10.9M (+142%) from $7.7M in Q2 2026 to $18.6M in Q3 2026.
What drove Recursion Pharmaceuticals's revenue change in Q3 2026?
Operating revenue +$10.8M (+147%); Grant revenue +$130K (+35%).